IONS - Ionis Pharmaceuticals Inc Stock Price, Fair Value and News

41.84USD+0.77 (+1.87%)Market Closed

Market Summary

USD41.84+0.77

Market Closed

1.87%

IONS Alerts

1 major insider sales recently.

IONS Stock Price

View Fullscreen

IONS RSI Chart

IONS Valuation

Market Cap

6.0B

Price/Earnings (Trailing)

-16.34

Price/Sales (Trailing)

7.6

EV/EBITDA

-19.97

Price/Free Cashflow

-18.07

IONS Price/Sales (Trailing)

IONS Profitability

EBT Margin

-42.40%

Return on Equity

-94.72%

Return on Assets

-12.25%

Free Cashflow Yield

-5.53%

IONS Fundamentals

IONS Revenue

Revenue (TTM)

787.6M

Rev. Growth (Yr)

113.65%

Rev. Growth (Qtr)

125.03%

IONS Earnings

Earnings (TTM)

-366.3M

Earnings Growth (Yr)

82.33%

Earnings Growth (Qtr)

93.72%

Breaking Down IONS Revenue

Last 7 days

-1.1%

Last 30 days

-3.8%

Last 90 days

-20.7%

Trailing 12 Months

11.2%

How does IONS drawdown profile look like?

IONS Financial Health

Current Ratio

5.9

Debt/Equity

1.62

Debt/Cashflow

-0.49

IONS Investor Care

Shares Dilution (1Y)

1.96%

Diluted EPS (TTM)

-2.56

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	576.0M	630.6M	615.0M	787.6M
2022	840.8M	848.8M	875.5M	587.4M
2021	707.5M	687.7M	660.7M	810.5M
2020	958.8M	940.5M	932.7M	729.3M
2019	752.5M	798.5M	821.0M	1.1B
2018	547.3M	552.8M	579.9M	599.7M
2017	425.5M	499.3M	506.7M	518.7M
2016	258.0M	176.0M	237.8M	346.6M
2015	248.6M	257.4M	274.9M	283.7M
2014	132.1M	151.1M	171.5M	214.2M
2013	122.2M	112.9M	124.9M	147.3M
2012	101.2M	123.7M	114.6M	102.0M
2011	99.7M	101.0M	93.1M	99.1M
2010	120.0M	112.5M	114.3M	108.5M
2009	0	112.0M	116.8M	121.6M
2008	0	0	0	107.2M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Ionis Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 16, 2024	birchler brian	sold	-37,698	41.6555	-905	evp, corp and development ops
Apr 16, 2024	baroldi joseph	sold	-166,641	41.5978	-4,006	evp, chief business officer
Apr 15, 2024	baroldi joseph	acquired	-	-	10,838	evp, chief business officer
Apr 15, 2024	birchler brian	acquired	-	-	1,875	evp, corp and development ops
Feb 29, 2024	swayze eric	acquired	20,827	34.425	605	officer level 14
Feb 29, 2024	geary richard s	acquired	20,792	34.425	604	officer level 14
Feb 29, 2024	bennett c frank	acquired	13,184	34.425	383	officer level 14
Feb 29, 2024	birchler brian	acquired	20,792	34.425	604	vice president level 14
Feb 29, 2024	monia brett p	acquired	18,520	34.425	538	ceo level 15
Feb 16, 2024	monia brett p	sold	-17,218	44.4924	-387	chief executive officer

Which funds bought or sold IONS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 22, 2024	MetLife Investment Management, LLC	reduced	-1.38	35,939	395,462	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	reduced	-38.72	-4,412,950	4,879,210	-%
Apr 22, 2024	Raymond James Financial Services Advisors, Inc.	reduced	-1.02	-104,830	585,572	-%
Apr 19, 2024	Handelsinvest Investeringsforvaltning	reduced	-34.18	-177,000	229,000	0.11%
Apr 19, 2024	Maryland State Retirement & Pension System	unchanged	-	-102,493	451,468	0.01%
Apr 19, 2024	Sumitomo Mitsui Trust Holdings, Inc.	reduced	-12.75	-3,223,590	9,548,310	0.01%
Apr 18, 2024	Diversified Trust Co	new	-	260,750	260,750	0.01%
Apr 18, 2024	ARK Investment Management LLC	reduced	-26.52	-35,693,200	60,683,600	0.42%
Apr 18, 2024	AlphaMark Advisors, LLC	reduced	-20.00	-8,000	17,000	0.01%
Apr 18, 2024	Koss-Olinger Consulting, LLC	sold off	-100	-230,000	-	-%

Are Funds Buying or Selling IONS?

Are funds buying IONS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own IONS

No. of Funds

IONS Alerts

1 major insider sales recently.

Unveiling Ionis Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	t. rowe price investment management, inc.	9.2%	13,201,453	SC 13G
Feb 13, 2024	bb biotech ag	6.0%	8,590,000	SC 13G/A
Feb 13, 2024	vanguard group inc	9.90%	14,203,481	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 26, 2024	blackrock inc.	6.3%	9,057,282	SC 13G/A
Jun 09, 2023	vanguard group inc	10.07%	14,414,917	SC 13G/A
Feb 14, 2023	t. rowe price investment management, inc.	8.2%	11,678,259	SC 13G
Feb 14, 2023	bb biotech ag	6.8%	9,635,000	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	9.54%	13,546,694	SC 13G/A

Recent SEC filings of Ionis Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 17, 2024	4	Insider Trading
Apr 17, 2024	4	Insider Trading
Apr 16, 2024	144	Notice of Insider Sale Intent
Apr 16, 2024	144	Notice of Insider Sale Intent
Apr 08, 2024	8-K	Current Report
Mar 13, 2024	3	Insider Trading
Mar 13, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading

Peers (Alternatives to Ionis Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.9B	6.8B	-0.89%	-25.81%	-8.47	5.83	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.4B	1.8B	-0.46%	-30.31%	-41.72	10.05	76.23%	61.08%
BMRN	16.9B	2.4B	5.17%	-8.18%	100.76	6.98	15.42%	18.43%
INCY	11.7B	3.7B	-8.90%	-30.41%	19.5	3.15	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-13.99%	-44.77%	-10.87	14.48	425.83%	18.94%
BBIO	4.4B	-	-15.28%	57.81%	-6.75	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-11.84%	-2.48%	-14.08	12.45	440.80%	-27.84%
ARWR	3.0B	240.7M	-11.98%	-22.42%	-9.98	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.29%	-15.38%	-45.68	3.85	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-3.94%	-8.31%	24.94	4.47	85.90%	-14.05%
NVAX	572.4M	983.7M	-12.98%	-52.88%	-1.05	0.58	-50.36%	17.16%
CRBP	395.6M	881.7K	7.90%	326.47%	-8.87	466.16	-77.61%	-5.33%
INO	233.7M	4.9M	-13.94%	-3.10%	-1.73	48.02	-54.97%	51.71%
IBIO	6.2M	2.1M	63.30%	36.92%	-0.23	2.14	-13.45%	66.37%

Ionis Pharmaceuticals Inc News

Latest updates

Ionis Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	125.0%	324,505,000	144,207,000	188,411,000	130,524,000	151,889,500	159,767,000	133,791,000	141,919,000	440,006,000	133,093,000	125,750,000	111,607,000	290,281,000	160,079,000	145,537,000	133,367,000	493,680,500	167,892,000	163,813,000	297,214,000	192,114,000
Costs and Expenses	15.0%	330,627,000	287,472,000	278,606,000	244,672,000	359,909,000	218,921,000	219,305,000	199,423,000	219,403,000	218,942,000	198,719,000	203,578,000	312,945,000	196,616,000	197,291,000	194,494,000	233,028,000	165,369,000	182,640,000	175,679,000	181,331,000
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	181,331,000
S&GA Expenses	1.5%	71,010,500	69,951,000	46,142,000	45,516,000	47,950,000	34,416,000	33,802,000	34,127,000	37,600,000	31,093,000	56,455,000	61,199,000	138,866,500	68,447,000	72,015,000	74,994,000	83,276,000	60,036,000	75,111,000	68,221,000	66,059,000
EBITDA Margin	31.6%	-0.39	-0.58	-0.41	-0.50	-0.40	0.04	0.00	0.02	-0.01	-0.37	-0.28	-	-	-	-	-	-	-	-	-	-
Interest Expenses	8.4%	4,558,000	4,203,000	2,291,000	1,608,000	1,731,000	2,139,000	2,130,000	2,122,000	2,238,000	2,340,000	2,357,000	2,414,000	2,434,000	2,428,000	2,441,000	2,207,000	-22,963,500	12,002,000	11,802,000	11,599,000	11,456,500
Income Taxes	-1.2%	6,518,500	6,600,000	7,800,000	11,380,000	8,110,000	300,000	2,260,000	1,094,000	334,000	-1,300,000	300,000	130,000	341,114,500	5,064,000	2,084,000	-3,072,000	42,314,500	-14,915,000	-6,900,000	31,000,000	-292,010,500
Earnings Before Taxes	98.0%	-2,766,500	-140,808,000	-77,448,000	-112,943,000	-44,330,000	-46,709,000	-102,875,000	-64,071,000	224,914,000	-83,773,000	-80,548,000	-89,739,000	-14,572,500	-31,550,000	-35,476,000	-52,954,000	230,257,500	3,517,000	-16,939,000	121,931,000	10,766,500
EBT Margin	30.6%	-0.42	-0.61	-0.45	-0.53	-0.44	0.01	-0.03	0.00	-0.04	-0.41	-0.31	-	-	-	-	-	-	-	-	-	-
Net Income	93.7%	-9,263,000	-147,410,000	-85,290,000	-124,323,000	-52,430,000	-46,992,000	-105,135,000	-65,165,000	224,613,000	-82,466,000	-80,875,000	-89,869,000	-85,987,000	-24,467,000	-25,636,000	-39,628,000	184,415,000	26,163,000	-876,000	84,443,000	320,078,000
Net Income Margin	30.1%	-0.47	-0.67	-0.49	-0.57	-0.46	0.01	-0.03	0.00	-0.04	-0.51	-0.46	-	-	-	-	-	-	-	-	-	-
Free Cashflow	130.3%	33,684,000	-111,163,000	-109,375,000	-144,464,000	-204,334,000	-29,971,000	-21,431,000	-34,355,000	201,185,000	-58,897,000	-67,010,000	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	1.9%	2,990	2,934	2,971	2,885	2,534	2,422	2,456	2,519	2,612	2,415	2,497	2,249	2,390	3,096	3,079	3,091	3,233	2,895	2,878	2,836	2,668
Current Assets	2.2%	2,642	2,585	2,617	2,543	2,203	2,152	2,191	2,253	2,345	2,156	2,238	1,989	2,131	2,537	2,531	2,558	2,721	2,408	2,414	2,374	2,208
Cash Equivalents	13.4%	399	352	425	309	276	315	522	543	869	633	565	414	398	633	530	486	683	248	273	376	279
Inventory	10.9%	28.00	26.00	26.00	22.00	22.00	21.00	20.00	24.00	25.00	23.00	24.00	22.00	22.00	22.00	24.00	23.00	18.00	19.00	19.00	11.00	9.00
Net PPE	0.2%	71.00	71.00	92.00	85.00	74.00	181	177	178	178	180	179	180	181	182	173	164	154	149	135	134	132
Liabilities	-0.6%	2,603	2,619	2,543	2,399	1,961	1,828	1,831	1,810	1,840	1,884	1,914	1,568	1,646	1,489	1,484	1,521	1,549	1,397	1,421	1,448	1,481
Current Liabilities	10.9%	448	404	288	259	312	283	268	228	241	280	294	295	599	245	231	258	273	232	241	252	280
Long Term Debt	1312.1%	625	44.00	114	545	-	544	621	543	619	618	617	541	540	450	284	280	435	596	587	577	568
LT Debt, Current	-	44.00	-	-	-	-	-	-	-	-	62.00	62.00	62.00	309	-	-	-	-	-	-	-	-
LT Debt, Non Current	1312.1%	625	44.00	114	545	-	544	621	543	619	618	617	541	540	450	284	280	435	596	587	577	568
Shareholder's Equity	22.6%	387	315	428	487	573	594	625	710	772	531	583	681	743	1,521	1,503	1,472	1,577	1,498	1,457	1,387	1,101
Retained Earnings	-0.5%	-1,795	-1,786	-1,639	-1,553	-1,429	-1,377	-1,330	-1,225	-1,159	-1,384	-1,302	-1,221	-1,131	-909	-878	-846	-707	-857	-883	-882	-967
Additional Paid-In Capital	3.1%	2,215	2,148	2,118	2,089	2,060	2,035	2,009	1,983	1,964	1,942	1,910	1,926	1,896	2,312	2,272	2,234	2,204	2,219	2,177	2,118	2,047
Shares Outstanding	0.7%	144	143	143	143	142	142	142	142	141	141	141	-	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	223	218	210	213	162	188	180	139
Float	-	-	-	4,243	-	-	-	3,805	-	-	-	4,675	-	-	-	6,748	-	-	-	7,483	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	130.1%	32,865	-109,022	-97,364	-133,992	-200,195	-24,429	-18,096	-31,650	203,687	-55,574	-62,652	-54,662	97,977	-10,275	-44,218	-7,592	277,839	-12,806	-27,111	107,705	115,508
Share Based Compensation	1.4%	26,336	25,963	26,562	26,948	25,689	23,837	24,502	26,236	22,259	30,537	30,021	37,861	95,040	45,844	48,443	40,790	35,010	24,127	41,932	45,505	34,102
Cashflow From Investing	-138.9%	-26,713	68,711	69,515	-325,640	212,147	-183,930	-3,304	-287,549	95,109	121,971	-101,030	78,856	187,849	101,940	79,695	-95,007	138,191	1,396	-110,687	-70,174	-326,207
Cashflow From Financing	226.2%	40,724	-32,267	143,538	492,087	-51,019	1,834	1,215	-7,325	-62,490	1,458	314,542	-7,577	-521,480	10,937	8,435	-94,501	19,225	-13,174	34,510	59,460	9,646
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	48.00	90,500	34,400	-	-	-	-

IONS Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue:
Revenue	$ 787,647	$ 587,367	$ 810,456
Expenses:
Cost of sales	9,133	14,116	10,842
Research, development and patent	899,625	833,147	643,453
Selling, general and administrative	232,619	150,295	186,347
Total operating expenses	1,141,377	997,558	840,642
Loss from operations	(353,730)	(410,191)	(30,186)
Other income (expense):
Investment income	89,041	25,331	10,044
Interest expense	(12,660)	(8,122)	(9,349)
Interest expense related to sale of future royalties	(68,797)	0	0
Gain (loss) on investments	(1,914)	(7,333)	10,103
Gain (loss) on sale of real estate assets	(161)	149,604	0
Other income (expense)	14,256	(7,274)	(9,760)
Loss before income tax benefit (expense)	(333,965)	(257,985)	(29,148)
Income tax benefit (expense)	(32,321)	(11,737)	551
Net loss	$ (366,286)	$ (269,722)	$ (28,597)
Basic net loss per share (in dollars per share)	$ (2.56)	$ (1.9)	$ (0.2)
Shares used in computing basic net loss per share (in shares)	143,190	141,848	141,021
Diluted net loss per share (in dollars per share)	$ (2.56)	$ (1.9)	$ (0.2)
Shares used in computing diluted net loss per share (in shares)	143,190	141,848	141,021
Commercial Revenue [Member]
Revenue:
Revenue	$ 308,591	$ 303,358	$ 342,395
SPINRAZA Royalties [Member]
Revenue:
Revenue	240,379	242,314	267,776
Other Commercial Revenue [Member]
Revenue:
Revenue	68,212	61,044	74,619
Research and Development Revenue [Member]
Revenue:
Revenue	479,056	284,009	468,061
Collaborative Agreement Revenue [Member]
Revenue:
Revenue	352,657	207,222	468,061
WAINUA Joint Development Revenue [Member]
Revenue:
Revenue	$ 126,399	$ 76,787	$ 0

IONS Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 399,266	$ 276,472
Short-term investments	1,931,935	1,710,397
Contracts receivable	97,778	25,538
Inventories	28,425	22,033
Other current assets	184,449	168,254
Total current assets	2,641,853	2,202,694
Property, plant and equipment, net	71,043	74,294
Right-of-use assets	171,896	181,544
Deposits and other assets	105,280	75,344
Total assets	2,990,072	2,533,876
Current liabilities:
Accounts payable	26,027	17,921
Accrued compensation	67,727	49,178
Accrued liabilities	147,894	140,101
Income taxes payable	2,151	6,249
0.125 percent convertible senior notes, net	44,332	0
Current portion of deferred contract revenue	151,128	90,577
Other current liabilities	8,831	7,535
Total current liabilities	448,090	311,561
Long-term deferred contract revenue	241,184	287,768
Liability related to sale of future royalties, net	513,736	0
Long-term lease liabilities	170,875	178,941
Long-term obligations	41,836	15,973
Total liabilities	2,603,386	1,960,989
Stockholders' equity:
Common stock, $0.001 par value; 300,000,000 shares authorized, 144,340,526 and 142,057,736 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	144	142
Additional paid-in capital	2,215,098	2,059,850
Accumulated other comprehensive loss	(32,645)	(57,480)
Accumulated deficit	(1,795,911)	(1,429,625)
Total stockholders' equity	386,686	572,887
Total liabilities and stockholders' equity	2,990,072	2,533,876
1.75 Percent Convertible Senior Notes [Member]
Current liabilities:
Convertible senior notes, net	562,285	0
0 Percent Convertible Senior Notes [Member]
Current liabilities:
Convertible senior notes, net	625,380	622,242
0.125 Percent Convertible Senior Notes [Member]
Current liabilities:
Convertible senior notes, net	$ 0	$ 544,504

About Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops Cimdelirsen to inhibit the production of growth hormone receptor; IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. Ionis Pharmaceuticals, Inc. was incorporated in 1989 and is based in Carlsbad, California.

CEO	Dr. Brett P. Monia Ph.D.
WEBSITE	ionispharma.com
INDUSTRY	Biotechnology
EMPLOYEES	796

Ionis Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Ionis Pharmaceuticals Inc? What does IONS stand for in stocks?

IONS is the stock ticker symbol of Ionis Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ionis Pharmaceuticals Inc (IONS)?

As of Mon Apr 22 2024, market cap of Ionis Pharmaceuticals Inc is 5.99 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IONS stock?

You can check IONS's fair value in chart for subscribers.

What is the fair value of IONS stock?

You can check IONS's fair value in chart for subscribers. The fair value of Ionis Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ionis Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IONS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ionis Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether IONS is over valued or under valued. Whether Ionis Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Ionis Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IONS.

What is Ionis Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 22 2024, IONS's PE ratio (Price to Earnings) is -16.34 and Price to Sales (PS) ratio is 7.6. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IONS PE ratio will change depending on the future growth rate expectations of investors.